Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

EGFR activating mutations and their association with response to platinum-doublet chemotherapy in Brazilian non-small cell lung cancer patients

Full text
Author(s):
Honma, Helen N. [1] ; Perroud, Jr., Mauricio W. [1] ; Leme, Mauricio S. T. [1] ; Barbeiro, Aristoteles S. [1] ; Saad, Bruna A. [2] ; Morcillo, Andre M. [3] ; Vassallo, Jose [4] ; Costa, Daniel B. [5] ; Zambon, Lair [1]
Total Authors: 9
Affiliation:
[1] Univ Estadual Campinas, Sch Med Sci, Dept Internal Med, Campinas, SP - Brazil
[2] Ctr Univ Lusiada, Sch Med, Sao Paulo - Brazil
[3] Univ Estadual Campinas, Dept Pediat, Campinas, SP - Brazil
[4] Univ Estadual Campinas, Sch Med Sci, Dept Anat Pathol, Campinas, SP - Brazil
[5] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol, Boston, MA 02215 - USA
Total Affiliations: 5
Document type: Journal article
Source: TARGETED ONCOLOGY; v. 9, n. 4, p. 389-394, DEC 2014.
Web of Science Citations: 2
Abstract

The aim of the study was to analyze the frequency of epidermal growth factor receptor (EGFR) mutations in Brazilian non-small cell lung cancer patients and to correlate these mutations with response to benefit of platinum-based chemotherapy in non-small cell lung cancer (NSCLC). Our cohort consisted of prospective patients with NSCLCs who received chemotherapy (platinum derivates plus paclitaxel) at the {[}UNICAMP], Brazil. EGFR exons 18-21 were analyzed in tumor-derived DNA. Fifty patients were included in the study (25 with adenocarcinoma). EGFR mutations were identified in 6/50 (12 %) NSCLCs and in 6/25 (24 %) adenocarcinomas; representing the frequency of EGFR mutations in a mostly self-reported White (82.0 %) southeastern Brazilian population of NSCLCs. Patients with NSCLCs harboring EGFR exon 19 deletions or the exon 21 L858R mutation were found to have a higher chance of response to platinum-paclitaxel (OR 9.67 {[}95 % CI 1.03-90.41], p=0.047). We report the frequency of EGFR activating mutations in a typical southeastern Brazilian population with NSCLC, which are similar to that of other countries with Western European ethnicity. EGFR mutations seem to be predictive of a response to platinum-paclitaxel, and additional studies are needed to confirm or refute this relationship. (AU)

FAPESP's process: 09/52574-5 - Correlation of the chemotherapy reply and overall survival in patients with non-small ß-cell lung cancer with biological markers through the genotypic analysis and protein expression
Grantee:Lair Zambon
Support Opportunities: Regular Research Grants